Sphera Funds Management’s Astria Therapeutics ATXS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-355,725
| Closed | -$4.66M | – | 100 |
|
|
2025
Q4 | $4.66M | Buy |
355,725
+104,500
| +42% | +$1.25M | 0.9% | 47 |
|
|
2025
Q3 | $1.83M | Sell |
251,225
-6,177
| -2% | -$41.8K | 0.39% | 75 |
|
|
2025
Q2 | $1.38M | Buy |
257,402
+67,602
| +36% | +$328K | 0.32% | 77 |
|
|
2025
Q1 | $1.01M | Buy |
189,800
+50,000
| +36% | +$350K | 0.23% | 90 |
|
|
2024
Q4 | $1.25M | Buy |
139,800
+3,218
| +2% | +$34.2K | 0.23% | 90 |
|
|
2024
Q3 | $1.5M | Sell |
136,582
-26,260
| -16% | -$292K | 0.24% | 92 |
|
|
2024
Q2 | $1.48M | Buy |
162,842
+50,000
| +44% | +$488K | 0.2% | 95 |
|
|
2024
Q1 | $1.59M | Sell |
112,842
-1,038,303
| -90% | -$12.9M | 0.22% | 85 |
|
|
2023
Q4 | $8.84M | Buy |
1,151,145
+570,546
| +98% | +$3.15M | 1.42% | 23 |
|
|
2023
Q3 | $4.33M | Buy |
580,599
+109,581
| +23% | +$934K | 0.79% | 45 |
|
|
2023
Q2 | $3.92M | Buy |
471,018
+50,000
| +12% | +$577K | 0.61% | 57 |
|
|
2023
Q1 | $5.6M | Sell |
421,018
-48,322
| -10% | -$653K | 0.94% | 38 |
|
|
2022
Q4 | $6.99M | Buy |
+469,340
| New | +$4.84M | 1.5% | 19 |
|
|
2021
Q2 | – | Sell |
-215,667
| Closed | -$3.74M | – | 135 |
|
|
2021
Q1 | $3.74M | Buy |
+215,667
| New | +$3.9M | 0.29% | 87 |
|
|
2018
Q1 | – | Sell |
-5,467
| Closed | -$489K | – | 112 |
|
|
2017
Q4 | $489K | Buy |
5,467
+666
| +14% | +$78.4K | 0.06% | 119 |
|
|
2017
Q3 | $611K | Hold |
4,801
| – | – | 0.09% | 109 |
|
|
2017
Q2 | $409K | Sell |
4,801
-1,666
| -26% | -$139K | 0.07% | 112 |
|
|
2017
Q1 | $621K | Buy |
6,467
+1
| +0% | +$138 | 0.12% | 100 |
|
|
2016
Q4 | $1.4M | Hold |
6,466
| – | – | 0.35% | 72 |
|
|
2016
Q3 | $2.39M | Buy |
6,466
+3,079
| +91% | +$811K | 0.39% | 66 |
|
|
2016
Q2 | $752K | Sell |
3,387
-447
| -12% | -$135K | 0.2% | 83 |
|
|
2016
Q1 | $1.16M | Buy |
3,834
+2,488
| +185% | +$858K | 0.25% | 78 |
|
|
2015
Q4 | $640K | Sell |
1,346
-4,112
| -75% | -$1.97M | 0.09% | 112 |
|
|
2015
Q3 | $2.6M | Sell |
5,458
-1,976
| -27% | -$1.41M | 0.33% | 74 |
|
|
2015
Q2 | $5.06M | Buy |
+7,434
| New | +$5.62M | 0.5% | 42 |
|
Sphera Funds Management's ATXS Position: Q1 2026 in Review
Sphera Funds Management sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 355,725 shares — an estimated $4.66M sold.
Sphera Funds Management first reported a position in ATXS in Q2 2015 and held it in 25 quarters. The position peaked at $8.84M in Q4 2023. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.
- Sphera Funds Management reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
- Sphera Funds Management sold 355,725 Astria Therapeutics shares in Q1 2026, an estimated $4.66M.
- Sphera Funds Management first reported a position in Astria Therapeutics in Q2 2015 and held it in 25 quarters.
- Sphera Funds Management's Astria Therapeutics position peaked at $8.84M in Q4 2023.
- 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.
Based on Sphera Funds Management's 13F filing for Q1 2026, filed 15 May 2026.